Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Is The Non-Cystic Fibrosis Bronchiectasis Market Size Likely To Evolve From 2025 Through 2034?
The non-cystic fibrosis bronchiectasis market size has seen robust growth in recent years. It is forecast to expand from $3.5 billion in 2024 to $3.7 billion in 2025, registering a compound annual growth rate (CAGR) of 5.8%. This historical expansion can be attributed to factors such as rising incidence and prevalence, advancements in diagnostic technologies, an increasing geriatric population, government support and funding, improved healthcare infrastructure, heightened diagnosis awareness, a growing geriatric population, and environmental exposure.
The non-cystic fibrosis bronchiectasis market size is anticipated to demonstrate robust expansion over the next few years. It is set to reach $4.68 billion in 2029, growing at a compound annual growth rate (CAGR) of 6.1%. This projected growth throughout the forecast period is attributed to advancements in personalized medicine, the emergence of new biomarkers, increased investment in respiratory medicine, expanding research and development efforts, various public health initiatives, the global aging population, and the creation of targeted therapies. Major trends expected during this timeframe include digital health solutions, a strong focus on targeted therapies, the integration of AI and machine learning, a shift towards home-based care, patient-centric approaches, and the proliferation of mobile health (mHealth) solutions.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp
Which Drivers Are Supporting Growth Of The Non-Cystic Fibrosis Bronchiectasis Market?
The non-cystic fibrosis bronchiectasis market is anticipated to experience growth due to the increasing incidence of respiratory diseases. These conditions encompass various ailments affecting the lungs and respiratory system, thereby hindering breathing and overall respiratory function. A primary cause of the escalating prevalence of respiratory diseases is growing environmental pollution, including both outdoor pollutants and indoor irritants like tobacco smoke. The increasing number of respiratory infections offers opportunities to advance the understanding, diagnosis, and management of non-cystic fibrosis bronchiectasis through targeted interventions and public health efforts. As an illustration, in June 2023, a report by the Office for Health Improvement and Disparities, a UK-based governmental body, revealed 4,622 notifications of scarlet fever Group A Streptococcus bacteria were received from week 37 to week 46 during the 2022-2023 season in England, with 851 notifications recorded in week 46 alone. This total far exceeds the average of 1,294 notifications (ranging from 258 to 2,008) for the same period (weeks 37 to week 46) over the previous five years. Therefore, the rising prevalence of respiratory diseases is set to drive the expansion of the non-cystic fibrosis bronchiectasis market.
What Are The Leading Segments Analyzed In The Non-Cystic Fibrosis Bronchiectasis Market?
The non-cystic fibrosis bronchiectasismarket covered in this report is segmented –
1) By Diagnosis: Computed Tomography (CT) Scan; Bronchoscopy; Chest X Ray; Lung Function; Sputum Culture Test; Blood Tests; Other Diagnosis Types
2) By Treatment: Surgery; Physiotherapy; Vaccination; Airway Pharmacotherapy; Antibiotics; Other Treatments
3) By End Use: Hospitals And Clinics; Ambulatory Care Centers; Other End Uses
Subsegments:
1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT); Standard CT
2) By Bronchoscopy: Flexible Bronchoscopy; Rigid Bronchoscopy
3) By Chest X-Ray: Standard Chest X-Ray; Digital Chest X-Ray
4) By Lung Function: Spirometry; Peak Flow Measurement
5) By Sputum Culture Test: Bacterial Culture; Fungal Culture; Viral Culture
6) By Blood Tests: Complete Blood Count (CBC); C-Reactive Protein (CRP); Immunoglobulin Levels
7) By Other Diagnosis Types: Sweat Test; Genetic Testing; Exhaled Nitric Oxide Test
How Are Emerging Market Trends Shaping The Non-Cystic Fibrosis Bronchiectasis Industry Landscape?
Leading companies operating in the non-cystic fibrosis bronchiectasis market are concentrating on personalized medicine approaches, such as nebulization solutions, to optimize the efficiency of drug delivery and patient adherence. Nebulization solutions provide advanced technology for the precise and effective administration of respiratory medications, thereby improving patient compliance and treatment outcomes. For example, in April 2022, Zambon S.P.A, an Italy-based multinational pharmaceutical company, received a US FDA designation for CMS I-neb therapy intended for patients with non-cystic fibrosis bronchiectasis (NCFB). CMS I-neb is an investigational treatment under development as a potential first-in-class inhaled therapy for adult patients with NCFB colonized with P. aeruginosa. NCFB is a chronic, progressive, and irreversible respiratory disease. This breakthrough designation validates the registrational path for CMS I-neb in NCFB and facilitates its potentially expedited development and review.
Which Major Industry Participants Are Leading The Non-Cystic Fibrosis Bronchiectasis Market Growth?
Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc, Teva Pharmaceutical Industries Ltd, Vertex Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr Reddy’s Laboratories Ltd, Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc, Insmed Incorporated, Genentech, Zydus Cadila, Santhera Pharmaceuticals, TSRL Inc
Download The Full Report For Exclusive Market Findings:
Which Regional Markets Are Contributing Most To The Non-Cystic Fibrosis Bronchiectasis Industry Expansion?
North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2024. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Non-Cystic Fibrosis Bronchiectasis Market Report:
https://www.thebusinessresearchcompany.com/customise?id=17209&type=smp
Browse Through More Reports Similar to the Global Non-Cystic Fibrosis Bronchiectasis Market 2025, By The Business Research Company
Cystic Fibrosis Cf Therapeutics Global Market Report 2025
Idiopathic Pulmonary Fibrosis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
Polycystic Ovarian Syndrome Treatment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model